Those looking to play a role in the development of medical uses of cannabis in the United States, listen up; Uncle Sam needs you. As reported by Marijuana Moment, a listing posted by the National Institute on Drug Abuse via the Federal Business Opportunities website last week asked for “capability statements” from businesses with the capacity to produce a variety of marijuana strains and products. Prospective firms must also be equipped with storage space for up to 5000 kilograms of cannabis stock.
The posting seems to be excellent news for those who have been waiting for the US to step up the cannabis stock available for critical drug trials. Such projects can only proceed with federally authorized marijuana and only one farm has been approved by the feds to provide such a supply. A University of Mississippi site currently holds the only authorization—as it has since it was approved way back in 1968.
What could have caused this long-awaited entrée to the expansion of cannabis science? Many will point to the recent resignation by request of Trump of Attorney General Jeff Sessions. Sessions’ well-known reputation as a salty adversary of legal cannabis may have played a major role in slowing